Antipsychotic agents: efficacy and safety in schizophrenia

• Published in: Drug, healthcare and patient safety healthcare and patient safety, 2012-01, Vol.4 (default), p.173-180
• Main Authors: de Araújo, Arão Nogueira, de Sena, Eduardo Pondé, de Oliveira, Irismar Reis, Juruena, Mario F
• Format: Article
• Language: English
• Subjects: Antipsychotic drugs; Antipsychotics; Bipolar disorder; Depression, Mental; Dopamine; Drug approval; Psychotropic drugs; Review; Schizophrenia
• ISSN: 1179-1365; 1179-1365
• DOI: 10.2147/DHPS.S37429

Antipsychotics have provided a great improvement in the management of people with schizophrenia. The first generation antipsychotics could establish the possibility of managing many psychotic subjects in an outpatient setting. With the advent of the second (SGA) and third generation antipsychotics (TGA), other psychiatric disorders such as bipolar depression, bipolar mania, autism, and major depressive disorder have now been approved for the use of these drugs for their treatment. Also, the administration of more specific assessment tools has allowed for better delineation of the repercussions of these drugs on symptoms and the quality of life of patients who use antipsychotic agents. In general, the SGA share similar mechanisms of action to achieve these results: dopamine-2 receptor antagonism plus serotonin-2A receptor antagonism. The TGA (eg, aripiprazole) have partial agonist activity at the dopamine-2 receptor site, and are also called dopaminergic stabilizers. The pharmacological profile of SGA and TGA may provide better efficacy against negative symptoms, and are less likely to produce extrapyramidal symptoms; however, the SGA and TGA are associated with many other adverse events. The clinician has to balance the risks and benefits of these medications when choosing an antipsychotic for an individual patient.